Northeast Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Northeast Pharmaceutical", stock code: 000597) is a listed company under Liaoning Fangda Group Industrial Co., Ltd. (hereinafter referred to as "Fangda Group"). The company was formerly the Northeast Pharmaceutical General Factory. It was founded in 1946. It has assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and has transported more than 1,300 cadres to the outside world. It is known as the cradle of my country's national pharmaceutical industry.

At present, Northeast Pharmaceutical has major business segments such as chemical raw materials, chemical preparations, pharmaceutical commerce, pharmaceutical engineering, and biomedicine, covering the entire industrial chain of pharmaceutical research and development, manufacturing, and distribution. It has an employee team of more than 8,500 people and a total assets of 12 billion yuan. The company mainly produces vitamin series drugs, anti-infection system drugs, obstetrics and gynecology system drugs, digestive system drugs, urinary system drugs, antiviral series drugs, cardiovascular and cerebrovascular series drugs, analgesic and cough-relieving series drugs, biological diagnosis series, big health There are ten series of fine products including the field series, as well as more than 400 chemical raw materials, pharmaceutical intermediates and preparation products. The leading products are exported to more than 100 countries and regions.

The company has a strong product manufacturing system. The preparation production base covers an area of ​​180,000 square meters, has more than 30 production lines, and an annual production capacity of 10 billion pieces (branches, pills, pellets, pellets, and bottles). The raw materials production base covers an area of ​​910,000 square meters. It is a national intelligent manufacturing demonstration factory for bulk raw materials and pharmaceutical intermediates. Its main products include vitamin C and series, L-carnitine series, Fosfomycin series, piracetam, and Kaprinline. Methyl esters, adamantine, sulfaluminum, berberine, chloramphenicol, etc. are fully extended to the downstream Northeast pharmaceutical preparation industry chain, forming a comprehensive competitive advantage that is difficult to replicate.

The company has a national advanced environmental protection treatment system to achieve all-round treatment of sewage, exhaust gas, noise and solid waste. The treatment capacity of the raw materials and drug sewage treatment system reaches 50,000 cubic meters per day. The incinerator can handle 9,000 tons of hazardous waste throughout the year, and exhaust emissions meet EU standards. The circular economy industrial park realizes resource processing of production waste and turns waste into treasure.

Northeast Pharmaceuticals has a complete quality management system, and its product quality complies with the new GMP, EP, USP, JP, BP, CP and other quality standards. Many products have successively passed international certifications such as EDQM, FDA, Japan Ministry of Health and Welfare, BRC, HALAL, KOSHER, etc. The leading products have passed the registration and quality audits in many countries and regions such as the United States, Europe, Japan, Brazil, Russia, and Poland.

Northeast Pharmaceutical is not only an important drug production and export base in China, but also has independent business companies such as drug research institutes, engineering design companies, equipment manufacturing and installation companies, international trading companies, metrology and testing companies, and hazardous chemical transportation companies, including 5. Our family is a high-tech enterprise.

The Northeast Pharmaceutical and Pharmaceutical Business Network covers all prefecture-level cities and counties in Liaoning and extends to the three northeastern provinces. The Northeast Pharmacy has more than 100 chain stores, and the pharmaceutical e-commerce business has achieved online and offline integration, and business model innovation continues to be promoted.